EXTON, PA — Lungpacer Medical has appointed healthcare finance executive Steven Pfanstiel as chief financial officer as the company moves to expand commercialization of its AeroPace System, an FDA-approved therapy for critically ill patients requiring mechanical ventilation.
The appointment comes as the Exton-based medical technology company seeks to scale operations and capitalize on what it describes as growing clinical adoption and reimbursement support for AeroPace, a neurostimulation therapy designed to help patients wean from mechanical ventilation.
Lungpacer disclosed the leadership change Thursday, bringing on an executive with nearly 25 years of experience in finance and operations across the medical device, biotechnology and healthcare sectors.
Pfanstiel most recently served as chief financial officer at Neuronetics, where he was involved in the integration of the Greenbrook clinic business and the company’s commercial expansion efforts. Before that, he held dual roles as chief operating officer and chief financial officer at Marinus Pharmaceuticals, helping oversee the commercial launch of anti-seizure treatment Ztalmy and the company’s sale to Immedica Pharma AB in 2025.
His previous leadership positions also include roles at LifeScan, OptiNose and Johnson & Johnson.
Lungpacer President and Chief Executive Officer Doug Evans characterized the hire as part of the company’s next phase of growth, pointing to the commercialization of AeroPace and expansion of the company’s operations.
“This is exactly the inflection point where Steve’s experience guiding healthcare companies through commercialization, operational scaling, and strategic financing creates real impact,” Evans stated.
Pfanstiel pointed to the company’s focus on treating patients who depend on mechanical ventilation and highlighted future development opportunities beyond AeroPace.
“The AeroPace System addresses a significant unmet need for the millions of patients who depend on mechanical ventilation each year,” Pfanstiel noted, adding that he plans to help accelerate commercialization efforts and support future growth initiatives.
The company also cited development efforts involving AeroNova, another program within its pipeline.
Pfanstiel holds an MBA in finance from Indiana University’s Kelley School of Business, a master’s degree in environmental systems engineering from Clemson University and a bachelor’s degree in physics from Wabash College.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.